NCT06804863

Brief Summary

This randomized, active-controlled, non-inferiority trial is scheduled to begin in May 2025 and will continue until June 2027. Inclusion criteria: (1) Patients with low-risk papillary thyroid cancer without lymph node metastasis who have undergone thyroid surgery (including both laparoscopic and open surgery) at the Department of Thyroid Surgery, West China Hospital, Sichuan University, (2) Aged between 18 and 90 years, (3) Chinese-speaking, (4) Capable of completing questionnaires and using a mobile phone and internet for intervention purposes, (5) No history of psychiatric disorders or use of psychotropic medications, (6) Voluntary participation and signing of an informed consent form. Exclusion criteria: (1) Patients with cervical lymph node metastasis, (2) Incomplete baseline data, (3) Uncontrolled chronic diseases, (4) Patients with other cancers. Online outpatient follow-up will be conducted by doctors from the Department of Thyroid Surgery at West China Hospital. One study participant will contact the patient, introduce the study, and obtain the informed consent form from willing participants. The research team members responsible for patient contact, registration, and randomization include the principal investigator, study coordinator, and specially trained research assistants. The management of the intervention group patients will be carried out by doctors from the corresponding departments. According to the protocol, patients assigned to online visits will switch to offline visits and exit the clinical trial under the following circumstances: (1) unresolved technical issues, (2) inability to perform a comprehensive assessment, (3) patient request for withdrawal. Other cross-cutting reasons include patient requests and scheduling conflicts. Baseline data (including age, gender, ethnicity, address, occupation), tumor-related information (including tumor histology, maximum tumor diameter, capsular invasion status, number of lymph node metastases), and surgical method will be collected from the hospital's information department. Participants will be given the DRS scale upon discharge and every two months thereafter to assess their regret status. For patients with high regret (DRS score \>25), a QoL scale will be further distributed to collect information about their quality of life. The REDCap randomization module will be used, and block randomization will be computer-generated with block sizes of 6 and 9, in a 1:1 ratio, to allocate patients to either the intervention or control group. The allocation sequence will be concealed, and the randomized results will be extracted by an independent data collection team. If intervention group patients need to complete the QoL scale, after completion, the doctor from the department corresponding to the factor with the highest score (i.e., the factor most closely related to the patient's regret state) will receive an SMS notification and will be required to contact the patient by phone or SMS within 24 hours to provide the intervention. If contact is not established within 24 hours of the intervention phase, the research participant will call the patient up to two times to clarify the reason.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
8mo left

Started May 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress69%
May 2025May 2027

First Submitted

Initial submission to the registry

January 27, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 3, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

May 1, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2027

Expected
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2027

Last Updated

February 3, 2025

Status Verified

January 1, 2025

Enrollment Period

2 years

First QC Date

January 27, 2025

Last Update Submit

January 27, 2025

Conditions

Keywords

Papillary thyroid cancerregretactive interventionprognosis

Outcome Measures

Primary Outcomes (1)

  • Clarifying the impact of immediate intervention on patients' postoperative regret psychology.

    Over a 12-month period after the start of the study, observe the declining trend of regret scores in patients who received immediate intervention compared to the control group.

    From enrollment to the end of follow-up at 12 months

Secondary Outcomes (1)

  • Main Factors Affecting Postoperative Regret in Low-Risk PTC Patients

    From enrollment to the end of follow-up at 12 months

Study Arms (2)

Intervening in patients with postoperative regret emotion.

EXPERIMENTAL

For the worst postoperative quality of life factors reported by patients, specialized doctors will provide immediate guidance and management via SMS or phone.

Behavioral: Postoperative Regret Reduction through Immediate Quality of Life Intervention

Only the patients' postoperative regret levels and quality of life scores will be collected.

NO INTERVENTION

Only the patients' postoperative regret levels and quality of life scores will be collected, without any additional interventions.

Interventions

Immediate intervention of the major impaired quality of life factors postoperatively to reduce patients' postoperative regret.

Intervening in patients with postoperative regret emotion.

Eligibility Criteria

Age18 Years - 90 Years
Sexall(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with low-risk papillary thyroid cancer without lymph node metastasis who have undergone thyroid surgery,
  • Aged between 18 and 90 years,
  • Chinese-speaking,
  • Capable of completing questionnaires and using a mobile phone and internet for intervention purposes,
  • No history of psychiatric disorders or use of psychotropic medications,
  • Voluntary participation and signing of an informed consent form.

You may not qualify if:

  • Patients with cervical lymph node metastasis,
  • Incomplete baseline data,
  • Uncontrolled chronic diseases,
  • Patients with other cancers.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West China Hospital

Chengdu, Sichuan, 610041, China

Location

MeSH Terms

Conditions

Thyroid NeoplasmsThyroid Cancer, Papillary

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid DiseasesAdenocarcinoma, PapillaryAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: The REDCap randomization module will be used, and block randomization will be computer-generated with block sizes of 6 and 9, in a 1:1 ratio, to allocate patients to either the intervention or control group. The allocation sequence will be concealed, and the randomized results will be extracted by an independent data collection team. If intervention group patients need to complete the QoL scale, after completion, the doctor from the department corresponding to the factor with the highest score (i.e., the factor most closely related to the patient's regret state) will receive an SMS notification and will be required to contact the patient by phone or SMS within 24 hours to provide the intervention. If contact is not established within 24 hours of the intervention phase, the research participant will call the patient up to two times to clarify the reason.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

January 27, 2025

First Posted

February 3, 2025

Study Start

May 1, 2025

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

May 30, 2027

Last Updated

February 3, 2025

Record last verified: 2025-01

Locations